These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37705003)

  • 1. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.
    Tsai CH; Chao CC; Hsieh ST; Yu AL; Wu YA; Cheng MF; Lee MJ; Chou CH; Shun CT; Hsueh HW; Jyh-Ming Juang J; Tseng PH; Su MY; Lin YH
    Orphanet J Rare Dis; 2023 Sep; 18(1):289. PubMed ID: 37705003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis.
    Wu YA; Yu AL; Cheng MF; Lin LC; Lee MJ; Chou CH; Shun CT; Hsueh HW; Juang JJ; Tseng PH; Lin SP; Su MY; Chao CC; Hsieh ST; Tsai CH; Lin YH
    Ther Adv Chronic Dis; 2024; 15():20406223231222828. PubMed ID: 38223905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tafamidis in Patients with Ala97Ser Hereditary Transthyretin Cardiac Amyloidosis: A Six-Month Follow-Up Study.
    Tsai CH; Yu AL; Wu YA; Su MY; Cheng MF; Chou CH; Shun CT; Hsueh HW; Juang JJ; Lee MJ; Tseng PH; Hsieh ST; Chao CC; Lin YH
    Acta Cardiol Sin; 2023 Jul; 39(4):619-627. PubMed ID: 37456942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
    Rettl R; Mann C; Duca F; Dachs TM; Binder C; Ligios LC; Schrutka L; Dalos D; Koschutnik M; Donà C; Kammerlander A; Beitzke D; Loewe C; Charwat-Resl S; Hengstenberg C; Kastner J; Eslam RB; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2022 Jun; 23(6):767-780. PubMed ID: 34788394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
    Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
    JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
    Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.
    Dobner S; Bernhard B; Ninck L; Wieser M; Bakula A; Wahl A; Köchli V; Spano G; Boscolo Berto M; Elchinova E; Safarkhanlo Y; Stortecky S; Schütze J; Shiri I; Hunziker L; Gräni C
    ESC Heart Fail; 2024 Oct; 11(5):2759-2768. PubMed ID: 38736040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
    Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
    Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis.
    Giblin GT; Cuddy SAM; González-López E; Sewell A; Murphy A; Dorbala S; Falk RH
    Eur Heart J Cardiovasc Imaging; 2022 Jul; 23(8):1029-1039. PubMed ID: 35274130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy.
    Rettl R; Duca F; Binder C; Dachs TM; Cherouny B; Camuz Ligios L; Mann C; Schrutka L; Dalos D; Charwat-Resl S; Badr Eslam R; Kastner J; Bonderman D
    Amyloid; 2023 Mar; 30(1):127-137. PubMed ID: 36251806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment.
    Wu YA; Tsai CH; Su MY; Chao CC; Cheng MF; Shun CT; Hsieh ST; Lin YH
    ESC Heart Fail; 2022 Dec; 9(6):4335-4339. PubMed ID: 36128649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.
    Yamaguchi S; Oda S; Kidoh M; Hayashi H; Takashio S; Usuku H; Nagayama Y; Nakaura T; Tsujita K; Hirai T; Aoki T
    Acad Radiol; 2024 Feb; 31(2):514-522. PubMed ID: 37775448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.
    Aus dem Siepen F; Meissner C; Hofmann E; Hein S; Nagel C; Hegenbart U; Schönland SO; Andre F; Frey N; Kristen AV
    Amyloid; 2024 Sep; 31(3):226-231. PubMed ID: 39018203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy.
    Takashio S; Morioka M; Ishii M; Morikawa K; Hirakawa K; Hanatani S; Oike F; Usuku H; Kidoh M; Oda S; Yamamoto E; Matsushita K; Ueda M; Tsujita K
    ESC Heart Fail; 2023 Aug; 10(4):2319-2329. PubMed ID: 37073415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis.
    Ichikawa Y; Oota E; Odajima S; Kintsu M; Todo S; Takeuchi K; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Hirata KI; Tanaka H
    Circ J; 2023 Mar; 87(4):508-516. PubMed ID: 36878601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.